Interpretation 141
Tier 2|
|
|
Variants
Primary Sites
Tumor Types
Interpretation
When mutated, HRAS can act as an oncogene. Somatic HRAS mutations have been associated with some cases of upper and lower urinary tract urothelial carcinoma, thyroid, and kidney cancers and in nevi. The frequency of HRAS mutations in upper and lower urinary tract urothelial carcinoma are about 10%. Interestingly, it has been shown that the HRAS mutation in lower urinary tract urothelial carcinoma may occur in tumors without FGFR3 mutations.
Citations
- Identification of HRAS mutations and absence of GNAQ or GNA11 mutations in deep penetrating nevi. Bender RP et a 2013 Modern pathology : an official journal of the United States and Canadian
- Nikiforov Y. Molecular diagnostics of thyroid tumors. Arch Pathol Lab Med. 2011 May;135(5):569-77
- Czerniak et al..Concurrent mutations of coding and regulatory sequences of the Ha-ras gene in urinary bladder carcinomas. Hum Pathol. 1992 Nov;23(11):1199-204
- Ascierto PA et al.. MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study. Lancet Oncol. 2013 Mar;14(3):249-56
- Bagrodia A, et al. Genomic Biomarkers for the Prediction of Stage and Prognosis of Upper Tract Urothelial Carcinoma. J Urol 2016;():
Last updated: 2016-04-17 17:47:49 UTC